Compare OKYO & JXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OKYO | JXG |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United Kingdom | China |
| Employees | N/A | 95 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.7M | 98.9M |
| IPO Year | 2021 | N/A |
| Metric | OKYO | JXG |
|---|---|---|
| Price | $1.58 | $11.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.33 | N/A |
| AVG Volume (30 Days) | ★ 56.9K | 5.3K |
| Earning Date | 07-18-2025 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $0.23 |
| 52 Week High | $3.35 | $11.80 |
| Indicator | OKYO | JXG |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 69.08 |
| Support Level | $1.47 | $3.57 |
| Resistance Level | $1.73 | $10.09 |
| Average True Range (ATR) | 0.09 | 0.57 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 52.72 | 57.24 |
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products. The Company's operations are located in the PRC and all of the Company's revenue is derived from sales to customers in the PRC region.